Rexahn Pharmaceuticals, Inc. RNN, a clinical stage
biopharmaceutical company focused on developing multi-indication therapeutics
in oncology and CNS, today announced top-line results from a Phase II clinical
study of Archexin^®, its clinical-stage oncology drug candidate. Archexin is
being developed as a potential first-in-class inhibitor of the Akt protein
kinase (Akt) in cancer cells.
The open label 2-stage study was designed to assess the safety and efficacy of
Archexin in combination with gemcitabine. Stage 1 was the dose finding portion
and stage 2 was the dose expansion portion using the dose identified in stage
1 to be administered with gemcitabine. The study enrolled 31 subjects aged
18-65 years with metastatic pancreatic cancer at four centers in the United
States and five centers in India. The primary endpoint was overall survival
following 4 cycles of therapy with a 6-month follow-up.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in